Yuri Takashi, Tsukamoto Reiko, Uehara Norihisa, Matsuoka Yoichiro, Tsubura Airo
Department of Pathology II, Kansai Medical University, Moriguchi, Osaka 570-8506, Japan.
In Vivo. 2006 Nov-Dec;20(6B):829-36.
There have been no precise evaluations of the effects of different durations of exposure to estrogen and progesterone pregnancy levels on mammary carcinogenesis risk. We examined such effects on the development of N-methyl-N-nitrosourea (MNU)-induced rat mammary carcinoma.
Female Lewis rats were administered a single intraperitoneal injection of 50 mg/kg MNU at 28 days of age, and then were either left hormone-untreated (control group), or underwent subcutaneous implantation of a 21-day release pellet containing 0.5 mg 17beta-estradiol and 32.5 mg progesterone (E/P pellet) at 42 days of age. The pellet was either replaced every 3 to 4 weeks throughout the experimental period (long-term E/P group), or was implanted only once (short-term E/P group). Circulating 17beta-estradiol and progesterone levels in the serum, and expression of estrogen receptor (ER) a and progesterone receptor (PgR) in the normal mammary gland were measured. The rats were sacrificed when they developed a mammary tumor with a diameter of > or =1 cm, or when they reached the age of 29 weeks.
In rats implanted with a single E/P pellet, circulating 17beta-estradiol and progesterone levels were significantly elevated 2 weeks after implantation, but returned to control levels 8 weeks after implantation; 17beta-estradiol transiently reached pregnancy levels. In normal mammary glands of rats sacrificed at 29 weeks of age, both long- and short-term E/P treatment decreased the percentage of ERalpha- and PgR-positive cells. Rats that received long- or short-term E/P treatment had a decreased incidence of mammary carcinoma with a diameter of > or =1 cm, compared to control rats. However, when histologically detected microcarcinomas (diameter <1 cm) were included for comparison, the E/P-treated groups exhibited an abrupt increase in the number of microcarcinomas from 22 to 25 weeks after MNU injection. Although short-term E/P treatment significantly suppressed mammary carcinomas of all sizes, long-term E/P treatment had no cancer-suppressing effect.
The duration of E/P treatment is an essential factor for the suppression of mammary carcinogenesis.
对于暴露于雌激素和孕激素孕期水平的不同时长对乳腺癌发生风险的影响,尚未有精确评估。我们研究了其对N-甲基-N-亚硝基脲(MNU)诱导的大鼠乳腺癌发生发展的影响。
雌性Lewis大鼠在28日龄时腹腔注射一次50mg/kg的MNU,然后要么不进行激素处理(对照组),要么在42日龄时皮下植入含0.5mg 17β-雌二醇和32.5mg孕酮的21天缓释微丸(E/P微丸)。在整个实验期间,微丸要么每3至4周更换一次(长期E/P组),要么只植入一次(短期E/P组)。检测血清中循环17β-雌二醇和孕酮水平,以及正常乳腺中雌激素受体(ER)α和孕激素受体(PgR)的表达。当大鼠出现直径≥1cm的乳腺肿瘤,或达到29周龄时,将其处死。
在植入单个E/P微丸的大鼠中,植入后2周循环17β-雌二醇和孕酮水平显著升高,但植入后8周恢复至对照水平;17β-雌二醇短暂达到孕期水平。在29周龄处死的大鼠的正常乳腺中,长期和短期E/P处理均降低了ERα和PgR阳性细胞的百分比。与对照大鼠相比,接受长期或短期E/P处理的大鼠直径≥1cm的乳腺癌发病率降低。然而,当纳入组织学检测到的微癌(直径<1cm)进行比较时,E/P处理组在MNU注射后22至25周微癌数量突然增加。虽然短期E/P处理显著抑制了各种大小的乳腺癌,但长期E/P处理没有抗癌作用。
E/P处理的时长是抑制乳腺癌发生的关键因素。